Skip to main content Accessibility help
Hostname: page-component-6c8bd87754-ncgjf Total loading time: 0.381 Render date: 2022-01-19T21:09:04.598Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Book contents

30 - Management of gestational trophoblast tumours

Published online by Cambridge University Press:  05 November 2015

Philip Savage
BC Cancer Agency, Victoria, BC, Canada
Louise Hanna
Velindre Cancer Centre, Velindre Hospital, Cardiff
Tom Crosby
Velindre Cancer Centre, Velindre Hospital, Cardiff
Fergus Macbeth
Velindre Cancer Centre, Velindre Hospital, Cardiff
Get access



Gestational trophoblast tumours (GTT) form a spectrum of rare diagnoses from the usually benign partial and complete molar pregnancies through to the aggressive malignancies of choriocarcinoma and placental site trophoblast tumour. The majority of care for the patients with molar pregnancies takes place in their local hospitals, with less than 10% of patients needing chemotherapy treatment. The cure rate for postmolar pregnancy GTT is 100% and most patients only need single-agent chemotherapy treatment. For the patients with rarer diagnoses of choriocarcinoma or placental site trophoblast tumour (PSTT), nearly all will be cured, even those presenting unwell with advanced metastatic cancer.

To provide an effective service in the UK for these rare conditions the Department of Health directly funds a national trophoblast service that cares for all patients with GTT. The trophoblast service has two specialist treatment centres, one at Weston Park Hospital in Sheffield and the other at Charing Cross Hospital in London. These centres, in addition to providing expert clinical care, also run the national human chorionic gonadotrophin (hCG) surveillance and follow-up programmes in conjunction with the Scottish follow-up centre in Dundee.

Although the main clinical care for GTT patients is centralised in the UK, it remains important for all oncologists to have a working knowledge of GTT because choriocarcinoma and PSTT can present as malignancies of unknown primary. In these patients, early involvement from the local oncology team in achieving the correct diagnosis and expediting treatment can be life-saving.

The pattern of GTT management in other countries varies; some countries have established centralised care, whereas in many other countries, patients are treated locally by doctors who are likely to only see a case every few years.

This chapter outlines the pathology, natural history and management of GTT based on the experience of the UK GTT service at Charing Cross Hospital in London.

Types of gestational trophoblast tumour

Gestational trophoblast tumours are divided into the premalignant partial and complete molar pregnancies and the malignant forms of invasive mole, choriocarcinoma and PSTT, as shown in Table 30.1. All forms of GTT constitutively produce hCG, although abnormalities of the molecule from some tumour cells can lead to false-negative results occasionally in some types of hCG assays (Cole et al., 2001).

Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)


Ahamed, E., Short, D., North, B., et al. (2012). Survival of women with gestational trophoblastic neoplasia and liver metastases: is it improving?J. Reprod. Med., 57, 262–269.Google Scholar
Alifrangis, C., Agarwal, R., Short, D., et al. (2013). EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J. Clin. Oncol., 31, 280–286.CrossRefGoogle ScholarPubMed
Bagshawe, K. D., Dent, J., Newlands, E. S., et al. (1989). The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT). Br. J. Obstet. Gynaecol., 96, 795–802.CrossRefGoogle Scholar
Bower, M., Rustin, G. J., Newlands, E. S., et al. (1998). Chemotherapy for gestational trophoblastic tumours hastens menopause by 3 years. Eur. J. Cancer, 34, 1204–1207.CrossRefGoogle ScholarPubMed
Cole, L. A., Shahabi, S., Butler, S. A., et al. (2001). Utility of commonly used commercial human chorionic gonadotropin immunoassays in the diagnosis and management of trophoblastic diseases. Clin. Chem., 47, 308–315.Google ScholarPubMed
Cole, L. A., Sasaki, Y. and Muller, C. Y. (2007) Normal production of human chorionic gonadotropin in menopause. N. Engl. J. Med., 356, 1184–1186.CrossRefGoogle ScholarPubMed
FIGO Oncology Committee. (2002). FIGO staging for gestational trophoblastic neoplasia 2000. Int. J. Gynaecol. Obstet., 77, 285–287.
Fisher, R. A., Lavery, S. A., Carby, A., et al. (2011). What a difference an egg makes. Lancet, 378, 1974.CrossRefGoogle ScholarPubMed
Goldstein, D. P., Garner, E. I., Feltmate, C. M., et al. (2004). Comment on ‘The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease.’ Gynecol. Oncol., 95, 421–422.CrossRefGoogle ScholarPubMed
Helwani, M. N., Seoud, M., Zahed, L.,et al. (1999). A familial case of recurrent hydatidiform molar pregnancies with biparental genomic contribution. Hum. Genet., 105, 112–115.CrossRefGoogle ScholarPubMed
Kim, S. J., Lee, C., Kwon, S. Y., et al. (2004). Studying changes in the incidence, diagnosis and management of GTD: the South Korean model. J. Reprod. Med., 49, 643–654.Google ScholarPubMed
McGrath, S., Harding, V., Lim, A. K., et al. (2012). Embolization of uterine arteriovenous malformations in patients with gestational trophoblastic tumors: a review of patients at Charing Cross Hospital, 2000–2009. J. Reprod. Med., 57, 319–324.Google Scholar
Newlands, E. S., Mulholland, P. J., Holden, L., et al. (2000). Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J. Clin. Oncol., 18, 854–859.CrossRefGoogle ScholarPubMed
Newlands, E. S., Holden, L., Seckl, M. J., et al. (2002). Management of brain metastases in patients with high-risk gestational trophoblastic tumors. J. Reprod. Med., 47, 465–471.Google ScholarPubMed
Palmieri, C., Dhillon, T., Fisher, R. A., et al. (2007). Management and outcome of healthy women with a persistently elevated beta-hCG.Gynecol. Oncol., 106, 35–43.CrossRefGoogle ScholarPubMed
Pezeshki, M., Hancock, B. W., Silcocks, P., et al. (2004). The role of repeat uterine evacuation in the management of persistent gestational trophoblastic disease. Gynecol. Oncol., 95, 423–429.CrossRefGoogle ScholarPubMed
Powles, T., Young, A., Sanitt, A., et al. (2006). The significance of the time interval between antecedent pregnancy and diagnosis of high-risk gestational trophoblastic tumours. Br. J. Cancer, 95, 1145–1147.Google ScholarPubMed
Savage, P. and Seckl, M. J. (2005). The role of repeat uterine evacuation in trophoblast disease. Gynecol. Oncol., 99, 251–252.CrossRefGoogle ScholarPubMed
Savage, P. M., Sita-Lumsden, A., Dickson, S., et al. (2013). The relationship of maternal age to molar pregnancy incidence, risks for chemotherapy and subsequent pregnancy outcome. J. Obstet. Gynaecol., 33, 406–411.CrossRefGoogle ScholarPubMed
Savage, P., Cooke, R., O'Nions, J., et al. (2015). Effects of single-agent and combination chemotherapy for gestational trophoblastic tumors on risks of second malignancy and early menopause. J. Clin. Oncol., 33, 472–478.CrossRefGoogle ScholarPubMed
Schmid, P., Nagai, Y., Agarwal, R., et al. (2009). Prognostic markers and long-term outcome of placental-site trophoblastic tumours: a retrospective observational study. Lancet, 374, 48–55.CrossRefGoogle ScholarPubMed
Sita-Lumsden, A., Short, D., Lindsay, I., et al. (2012). Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009. Br. J. Cancer, 107, 1810–1814.CrossRefGoogle Scholar
Stenman, U. H., Alfthan, H. and Hotakainen, K. (2004) Human chorionic gonadotropin in cancer. Clin. Biochem., 37, 549–561.CrossRefGoogle Scholar
Wang, J., Short, D., Sebire, N. J., et al. (2008). Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE). Ann. Oncol., 19, 1578–1583.CrossRefGoogle Scholar
Hancock, B. W., Seckl, M. J., Berkowitz, R. S., et al. (2009). Gestational Trophoblastic Disease, 3rd edn. Sheffield: International Society for the Study of Trophoblastic Diseases.Google Scholar
International Society for the Study of Trophoblastic Diseases (ISSTD). (accessed December 2014).
Royal College of Obstetricians and Gynaecologists (RCOG). (2004). The Management of Gestational Trophoblastic Neoplasia. RCOG Guideline No. 38. London: Royal College of Obstetricians and Gynaecologists.
Seckl, M. J., Sebire, N. J. and Berkowitz, R.S. (2010). Gestational trophoblastic disease. Lancet, 376, 717–729.CrossRefGoogle ScholarPubMed

Send book to Kindle

To send this book to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle.

Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats

Send book to Dropbox

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Dropbox.

Available formats

Send book to Google Drive

To send content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about sending content to Google Drive.

Available formats